Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

340B Exemptions Offer Manufacturers ‘Significant’ Incentives To Seek Orphan Status – HHS OIG

Executive Summary

Office of Inspector General report explores the orphan drug status of a set of blockbuster drugs with the highest level of spending in Medicare.

You may also be interested in...



Orphan Drug Spending: Could Sequence Of Indications Offer Pricing Policy Solution?

Focusing on orphan-first drugs may be best route to address pricing concerns, Health Affairs study suggests after finding that just one-fifth of spending on 15 top-selling partial orphan drugs was for the drugs’ rare disease indications.

Medicare And Alzheimer’s Drugs: Recent NCDs Mainly Omit Research Requirement, Biogen Notes

Biogen suggests potential precedents in past coverage decisions for upcoming Medicare determination on Aduhelm and other amyloid-directed monoclonal antibodies during earnings call.

Semglee's Boost On Express Scripts Formulary Reflects Interchangeability – And Rebates

First interchangeable insulin biosimilar gains preferred status on one of the largest national formularies in the US.

Topics

Related Companies

UsernamePublicRestriction

Register

PS145034

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel